MeiraGTx (MGTX) shares rose Thursday after the company said it is forming a joint venture with Hologen as part of a strategic collaboration to develop AAV-GAD for Parkinson's disease.
The stock was up over 25% in recent trading after rising as much as 32.4% earlier. Trading volume topped 5.5 million shares versus a daily average of about 318,000.
The venture, Hologen Neuro AI, will be funded with a capital of up to $230 million from Hologen, a developer of generative AI foundation models of clinical data for drug development.
MeiraGTx said it will get $200 million in upfront cash at closing of the agreement.
Hologen will also fund a portion of MeiraGTx's manufacturing operations and will own a minority stake in its manufacturing subsidiary, the company said.
Price: 8.12, Change: +1.71, Percent Change: +26.68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.